

**COMBINED AMENDMENT & PETITION FOR EXTENSION OF
TIME UNDER 37 CFR 1.136(a) (Large Entity)**

Docket No.

027378 (PHA-00988/1/US)

In Re Application Of: **Thomas E. Barta**

NOV 17 2005

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/618,288	April 25, 2003	Emily B. Bernhardt	26648	1624	7868

Invention: PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS

COMMISSIONER FOR PATENTS:

This is a combined amendment and petition under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of July 14, 2005 in the above-identified application.

The requested extension is as follows (check time period desired):

One month Two months Three months Four months Five months

from: October 14, 2005 *Date* until: November 14, 2005 *Date*

The fee for the amendment and extension of time has been calculated as shown below:

CLAIMS AS AMENDED


	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	2 -	374 =	0	x \$50.00	\$0.00
INDEP. CLAIMS	2 -	28 =	0	x \$200.00	\$0.00
FEE FOR AMENDMENT					\$0.00
FEE FOR EXTENSION OF TIME					\$120.00
TOTAL FEE FOR AMENDMENT AND EXTENSION OF TIME					\$120.00

11/18/2005 CNGUYEN 00000108 191025 10618288

01 C:1251 120.00 DA

COMBINED AMENDMENT & PETITION FOR EXTENSION OF
TIME UNDER 37 CFR 1.136(a) (Large Entity)

Docket No.
027378 (PHA-00988/1/US)



The fee for the amendment and extension of time is to be paid as follows:

A check in the amount of _____ for the amendment and extension of time is enclosed.

Please charge Deposit Account No. 19-1025 in the amount of \$120.00

The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No.

- Any additional filing fees required under 37 C.F.R. 1.16.
- Any patent application processing fees under 37 CFR 1.17.

If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



Philip B. Polster, II
Signature

Philip B. Polster, II Reg. No. 43,864
Corporate Counsel
Pharmacia Corporation of Pfizer Inc.
P.O. Box 1027
Chesterfield, Missouri 63006
314.274.9094

CC:

Dated: November 14, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on November 14, 2005.

(Date)

Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence